

## Prescription Non-Steroidal Anti-Inflammatory Drugs: Pattern and Nephrotoxicity

### ABSTRACT

**Background:** Non-steroidal anti-inflammatory drugs (NSAIDs) are very common “over-the-counter” commonly abused drugs used in treating fever, pain and inflammatory conditions. They inhibit prostaglandins and can cause kidney disease and hypertension, particularly in stressed states like dehydration and exercises.

**Objectives:** To assess prescription pattern and effects of common NSAIDs on the kidneys.

**Methods:** One hundred frequent NSAIDs users (daily use  $\geq 4$  weeks) and 100 healthy controls, who had no known risk factor for kidney disease and gave consent were recruited. Blood samples for serum electrolytes, urea and creatinine, haemoglobin concentration and urine samples for dip strip, and 24 hour protein were collected and analysed.

**Results:** The mean age of the controls, all NSAIDs users, NSAIDs users without kidney dysfunction (KD) and NSAIDs users with KD were  $46.04 \pm 14.21$  years,  $46.5 \pm 14.2$  years,  $41.84 \text{ years} \pm 14.52 \text{ yrs}$  and  $63.04 \pm 4.21$  years respectively,  $P=0.03$ . The mean estimated glomerular filtration rate (eGFR) was significantly lower in frequent NSAIDs users than controls,  $P<0.001$ . Ibuprofen was the most nephrotoxic and, nephrotoxicity was positively related to combination therapy ( $P<0.001$ ) and duration of use ( $P=0.03$ ). Herbal medicines significantly increased the risk of KD,  $P=0.01$ . Predictors of KD were advancing age, longer duration of NSAIDs use, Ibuprofen use and combined NSAIDs

**Conclusion:** Frequent NSAIDs use, common in Orthopaedic units, could be complicated by kidney dysfunction. Ibuprofen, followed by ketoprofen, was the most nephrotoxic. Observed risk

factors for NSAIDs induced nephrotoxicity included advancing age, herbal remedies, Ibuprofen and combination therapy.

**Keywords:** Non-steroidal anti-inflammatory drugs; Frequent-users; Nephrotoxicity

**Short Running Title:** Prescription NSAIDs: Pattern and Nephrotoxicity.

## **INTRODUCTION**

Non-steroidal anti-inflammatory drugs (NSAIDs) are agents commonly used in treating fever, pain, inflammatory conditions and tiredness.[1] They are cheap, often taken without prescription and their use is not regulated by law hence they are commonly abused, defined as use in excessive amount or for purposes different from what they are meant for, for instance, body weakness [2]. The use of these “over-the counter” (OTC) drugs is common among manual labourers and the elderly [2,3]. NSAIDs are broadly classified into eight groups based on their chemical structures and pharmacokinetics [4]. These are: Salicylates (Aspirin), Propionic acids (Ibuprofen, Ketoprofen), Oxicams (Meloxicam), Acetic acid (Indomethacin), Pyrazolones (Phenylbutazole), Cyclo-oxygenase II inhibitors (Celecoxib), Fenamates (Mefenamic acid) and Benzene Acetic Acid Derivatives (Diclofenac).

The duration and frequency of NSAIDs use could be dependent on whether it was prescribed or not.[5] Paulose-Ram et al [6] defined frequent use of an analgesic agent as daily use of up to a month. The authors found a 14% prevalence of frequent users of these drugs in the United States. The prevalence of NSAIDs use in a community survey was found to be 13%, and of this, 22.6% were abusers [2]. Manual labourers often take these drugs for tiredness, pain and aches. In some cases where NSAIDs are prescribed, there isn't sufficient knowledge on the part of some

prescribers concerning possible adverse effects and conditions in which these effects are enhanced [5-7].

In Nigeria, a prevalence of 60% and 70% NSAIDs use is reported among males and females aged over sixty five years respectively. The authors attributed the high prevalence to arthritis and other musculoskeletal conditions that are common in this population.[8] Renal complications from the use of these drugs is reported to cause about 2% of users to discontinue the drugs [9]. In the United States, about 12.1% of the population is reported to use NSAIDs regularly, 2.5 million are diagnosed with NSAIDs-induced kidney dysfunction annually, and a new patient is daily admitted to dialysis from NSAIDs use [11].

Exercises under the sun reduces the glomerular filtration rate (GFR) by 19%, and with dehydration, decreases the GFR by 51% [12]. It is advised that NSAIDs use just before, and during exercise should be discouraged particularly in the presence of dehydration, liver disease or heart failure [13]. The higher risk of hyponatremia, and kidney dysfunction in marathoners and manual labourers have been attributed to the dehydration that results from sweating.[14]. The inhibition of the activities of renal prostaglandins abolishes the glomerular afferent arteriolar dilatation which is a vital compensatory mechanism in stressed states [5, 9, 11].

The use of NSAIDs in orthopaedic units is mostly prescription based unlike OTC use that is common at the community level. Literature is still growing as it relates to the nephrotoxicity or otherwise of NSAIDs. There is paucity of literature in the less developed nations where the use of these drugs is more common. In this study, we compared the kidney function of frequent NSAIDs users with healthy controls.

## Methods

### Study design

This was a hospital-based comparative study that lasted 24 months (July 2016-June 2018) at the nephrology unit of Federal Medical Centre, Abeokuta, Nigeria.

#### Study population

One hundred frequent NSAIDs users without any known risk for kidney disease, and age and sex-matched healthy controls who had no known risk factor for kidney disease, participated. The NSAIDs users were recruited from the orthopaedic outpatient clinics while the controls were healthy hospital staffs. NSAIDs users were shown packets, sachets and containers of the common NSAIDs in the locality to ascertain those used by them alone or in combination.

#### Exclusion criteria

Participants with hypertension, diabetes, sickle cell anemia, heart failure, chronic liver disease, proteinuria, glycosuria, ultrasound-diagnosed kidney disease and any condition known to impact negatively on kidney function were excluded.

#### Study protocol

Data was obtained from participants' case notes and from history and entered into a structured interviewer-administered questionnaire.

The height and weight were measured with a standiometer and a weighing scale. The blood pressure (BP) in mmHg, was taken in sitting position (with the back and the arm rested on a support) using a mercury sphygmomanometer (ACCOSON, England) after participants had rested for 5 minutes. Participants were then given a 4-6 litre plastic can treated with tetraoxosulphate VI acid ( $H_2SO_4$ ) for 24 hour urine collection. They were asked to empty their first urine (on walking up in the morning) and discard, and document the time. They collected subsequent urine into the plastic can. Twenty-four hours after the documented time, they emptied the last urine for the test into the can and immediately brought it to the hospital central laboratory

for determination of total protein, electrolytes and creatinine clearance, after which they presented at the clinic for their routine visit. Two on-the-spot urine samples were collected during urine submission, for albumin creatinine ratio (ACR) and dip strip urinalysis.

For the ACR test, a strip with its reagent pad was taken from its container [SIEMENS Microalbustic, REF 2087 (04960872)] which was then capped immediately (to minimise the exposure of the remaining strips to light and air) and immersed almost completely in the urine. It was then removed and the result for the albumin was read after 50 seconds and that of creatinine was read after 60 seconds by matching the colour changes with the corresponding colour on the strip bottle and the values were recorded.

During urine submission, blood was collected into an EDTA containing bottle for estimation of haemoglobin estimation, and into a Lithium heparin bottle for creatinine, urea, sodium, potassium, bicarbonate and chloride. Creatinine based eGFR was calculated using the CKD-EPI formula.[15] Continuous variables were presented as mean with standard deviation which were compared using Student t-test. Categorical variables were presented as proportions with frequencies and compared using Chi-square. Independent predictors of kidney dysfunction were determined using multiple regression analysis. A P-value of  $< 0.05$  was considered statistically significant.

#### Definition of terms

Frequent NSAIDs users: those that took at least, a unit of the drug (tablet, caplet, capsule, suspension, syrup, patch, cream or ointment) daily for at least 4 weeks [5, 6]

Kidney dysfunction (KD): eGFR of  $< 60$  ml/min [16]

Hypertension:  $\geq 140/90$  mmHg or taking anti-hypertensive drugs. [17]

Diabetes:  $\geq 11.1$ mmol or taking anti diabetic drugs. [18]

Anemia: Hemoglobin concentration <13g/dL.[19,20]

Metabolic acidosis: serum bicarbonate < 22mmol/L [21]

Dip strip proteinuria:  $\geq$ +1 [22]

Microalbuminuria: urine ACR >3.4mg/mmol (>30mg/g) [23, 24]

Continuous variables are presented as mean with standard deviation using student's t-test and categorical data as proportions using chi-square. Multiple regression analysis showed Ibuprofen use, age, duration, and number of NSAIDs used as independent predictors of kidney function in NSAIDs users. Statistical significance was with a p-value of < 0.05.

## RESULTS

The frequent NSAIDs users and control group were each made up of 51 females and 49 males. The mean age of the NSAIDs users was  $46.54 \pm 14.52$  years compared with the controls  $46.04 \pm 14.21$  years,  $P=0.38$ . A majority of the NSAIDs users (53%) were in the 40-59yrs age group. Thirty eight (38%) NSAIDs users had arthritis, 18 (18%) had low back pain, 12 (12%) had post fracture pain and 10 (10%) had spondylitis. Three NSAIDs users were taking Aceclofenac, 24 were taking Diclofenac, 6 took Ibuprofen, 10 took Ketoprofen, 16 took Meloxicam while 41 took more than one NSAID (combination therapy).

The mean weight of the NSAIDs users was ( $71.74 \pm 14.92$  kg) compared to  $67.72 \pm 12.54$  kg for the controls,  $P=0.03$ . The mean BMI and systolic blood pressure of NSAIDs users were significantly higher than controls (Table 1). The mean haemoglobin concentration of NSAIDs users was significantly lower than controls,  $P=0.02$ . The serum potassium, chloride, creatinine, and 24-hour urinary protein were significantly higher in NSAIDs user than controls while the serum bicarbonate, eGFR ( $P<0.001$ ) and haemoglobin concentration were significantly lower in NSAIDs users than controls.

The mean age, weight and systolic blood pressure of NSAIDs users with kidney dysfunction (KD) were higher than NSAIDs users without KD,  $P=0.03$ ,  $P=0.01$  and  $P=0.04$  respectively. The duration of NSAIDs use was positively related to the mean systolic and diastolic blood pressures,  $P=0.001$  and  $P=0.001$  and negatively correlated with mean eGFR,  $P<0.001$  and haemoglobin concentration,  $P=0.002$  (Table 2). NSAIDs users with kidney dysfunction had lower mean haemoglobin concentration but higher proteinuria compared with those without KD. Of the NSAIDs users that took a single NSAID, Ibuprofen users had the lowest mean eGFR, followed by Aceclofenac users while those that took Diclofenac had the highest eGFR. Combined NSAIDs users had lower mean eGFR compared with that of any single NSAID users.

Twenty two (22%) NSAIDs users had kidney dysfunction (GFR  $<60$ ml/min) compared to 6% in the controls. Using the ACR, 29.3% of the 41 (41%) NSAIDs users that took combined NSAIDs had kidney dysfunction while 10.2% of the 59 (59%) that took a single NSAID had KD. Participants that used higher doses of NSAIDs had higher urine ACR (Table 3).

Among the NSAIDs users, the risk of kidney dysfunction was higher in females ( $P=0.03$ ), advancing age ( $P<0.001$ ), use of herbal remedies ( $P<0.001$ ) and in participants with arthritis,  $P<0.001$  (Table 4).

Multiple regression analysis (Table 5) showed advancing age, longer duration of NSAIDs use, Ibuprofen, and use of combination drugs, as predictors of kidney dysfunction.

## DISCUSSION

The prevalence of kidney dysfunction in NSAIDs users was 22% and was positively related to the number, dose and duration of NSAIDs use. The most common reason for NSAIDs use was arthritis. There was a positive relationship between the eGFR and serum levels of bicarbonate and haemoglobin. The higher prevalence of NSAIDs use in this study compared with the 13%

found in a community study in Nigeria and the 14% reported in the United States, could be attributed to the study's (hospital-based) design and participants' NSAIDs-requiring conditions. [2, 6] Another study in Nigeria also attributed NSAIDs use to the treatment of painful conditions and found a prevalence of NSAIDs use among males and females aged over 65 years to be 60% and 70% respectively, in a population that included diabetics and hypertensives, (groups that were both excluded from our study).[8] Though the authors, did not assess kidney function in their study, they reported a poor response to anti-hypertensives among hypertensives who used the two drug groups concurrently. An implication of this is a higher prevalence of complications of poorly treated hypertension like kidney disease in this population group.[25]

The prevalence of KD in this study is close to 19% reported by Schwarz et al [26] in people that took these drugs daily for more than 4 weeks, and had progressed from acute kidney injury (AKI) to chronic kidney disease (CKD). The CKD-EPI equation used in this study is found to be more reliable than the MDRD when GFR is greater than 60mls/min as it does not overestimate the GFR. Some of the participants used in studies that used MDRD would have been classified as having KD using the CKD-EPI formula.[15, 27]

The positive correlation between participants' age and KD mirrors findings from other studies that found increasing age as a risk factor for kidney disease. [28] The renal insults from exogenous nephrotoxins in the elderly, in whom the renal reserve is often poor, could easily be heightened, and could be overwhelming.[29] The higher risk of nephropathy in females is in agreement with previous studies, and could be multifactorial, with factors like the lower baseline GFR, the higher frequency of NSAIDs use in them, and perhaps, cultural biases that tend to limit relatively, the accessibility of females to healthcare in the local setting.[16, 30-31] Moreover, females, having more body fats with consequent larger volumes of distribution of drugs are

expected to carry a higher risk for drug toxicities, particularly in excessive doses. [32] Females, being of smaller body sizes and weights, receive larger drug concentration per unit body tissue, and this could lead to higher toxicities in excess doses, particularly as most adult prescriptions are not weight-based. The lower levels of cytochrome P450 enzyme inducers in females is associated with lower drug degradation in them, resulting in larger serum levels of drugs compared to males. [33]

The negative relationship between the BMI and kidney function agrees with findings that reported an association between higher BMI and risk of new onset kidney disease.[34] Renal hyperfiltration, common in obesity, is associated with nephromegally, higher intraglomerular pressure and kidney damage. The resulting necrosis of the nephron leads to compensatory nephromegally of the remaining nephrons. The interplay of forces relating the kidney size with hyperfiltration, kidney damage and proteinuria is well reported in diabetic nephropathy, obesity, focal segmental glomerulosclerosis (FSGS) and NSAIDs-induced kidney disease. [35, 36]

The association between rising blood pressure (within normal range) and NSAIDs-induced kidney dysfunction in this study mirrors findings by Pirkle et al [37] that established a link between hypertension and kidney disease. This may also give credence to some researchers that favour lower “normal blood pressure” particularly in Africans and African Americans (AA) whom studies have reported to suffer worse consequences of blood pressure increases and hypertension.[38, 39] The higher renal and systemic resistance induced by NSAIDs is consequent upon their inhibition of PGs-induced vasodilatation and this could lead to the activation of the renin angiotensin aldosterone system (RAAS) pathway associated with vasoconstriction, fluid retention, higher effective blood volume (EBV) and, interstitial fluid volume [28, 37]

The higher serum potassium seen in NSAIDs users could result from the inhibition of Na/K/H ATPases which leads to higher potassium extracellular shift with concurrent higher intracellular sodium shift resulting in hyperkalaemia and low sodium, similar to findings by Firestein et al [40] Though NSAIDs induced glomerulopathy is less commonly reported compared to tubulointerstitial (TIN) injury, secondary glomerular affectation from the progression of a primary TIN disease could lead to lowered glomerular filtration, further worsening the nitrogenous wastes retention associated with kidney dysfunction. [5,34] The proteinuria in those with KD could be attributed majorly to a more severe form of TIN in them, or a TIN with a glomerular back-leak effect or rarely a primary glomerulopathy which fortunately was less likely considering the fact that nephrotic range proteinuria was not found in any of the participants, unlike in previous studies that reported the contrary.[24, 41] The exclusion of conditions that negatively impact kidney function is most likely responsible for the absence of nephrotic range proteinuria in the participants.[24]

Urinary creatinine clearance has been reported to be an unreliable estimate of the eGFR as the high proximal tubular secretion of creatinine could give falsely elevated urinary creatinine values and therefore higher creatinine clearance. [42] NSAIDs-induced TIN could contribute to glomerular proteinuria that results from glomerular hypertension leading to increased glomerular filtration of normally unfiltered proteins. This is followed by increased tubular absorption and metabolism of these proteins which further damages the tubules leading to tubular epithelial injury and sloughing, obstruction to flow, eventually leading to increased tubular secretion of low molecular weight (LMW) proteins. [23-24, 43] This cascade of events which typifies NSAIDs-induced proteinuria with nephrotic syndrome as a consequences of PG inhibition could

explain the positive relationship between proteinuria and KD in this study despite NSAIDs' known anti-inflammatory properties. [44]

The mostly tubular LMW protein loss that complicates tubular and interstitial injury could lead to reduced renal tubular epithelium secretory capacity and the loss of polarity between the apical and basolateral membranes, a form of acute tubular necrosis, similar to findings by Vegal et al. [45] The positive relationship between the systolic BP and nephrotoxicity mirrors findings by Ghosh et al.[46] Proteinuria leads to increased hepatic production of atherogenic lipids and this increases the risk of plaque deposition, atherosclerotic vessel wall stiffening, increased peripheral resistance and elevated SBP. [47]

The higher frequency of anemia in NSAIDs users compared to healthy controls agrees with previous findings and this could be multifactorial in origin.[20, 48] The congestion involving the hepatic bed and gastrointestinal tract commonly leads to anorexia, early satiety, reduced digestion, absorption and assimilation, factors that contribute to low substrate delivery for erythropoiesis.[49] The predominant interstitial affection in NSAIDs-induced nephropathy can depress erythropoietin production by the fibroblast cells of the peritubular interstitium. These drugs can cause gastritis and small intestinal mucosal injury with reduction in serum iron, folic acid, B<sub>12</sub> and other substrates, hence the anaemia that is common in them. [5, 30, 40]

The higher frequency of metabolic acidosis (MA) in NSAIDs users mirrors findings in previous findings that reported higher prevalence of MA from exogenous nephrotoxins. [20, 50] The tubular injury induced by these drugs inhibit the Na/K ATPase, and the intercalated cells disrupting the exchange mechanisms that mediates potassium exchange, with hydrogen ions retention as a consequence.[51]

In this study, the duration of NSAIDs use was directly related to the risk of kidney damage as it was earlier found that NSAIDs use for more than a month increased the risk of progression from AKI to CKD.[26] Prolonged NSAIDs use would prevent the healing process that should follow an episode of AKI as recurrent episodes of injury-repair/healing with reperfusion injury lead to interstitial fibrosis, glomerular sclerosis, tubular wall dilatation, atrophy and scarring. This can indeed progress to severe diminution in kidney function with morphological changes leading to the “sick indented, calcified kidneys” (SICK) seen in long standing NSAIDs abuse. [52] The increased nephrotoxicity associated with Ibuprofen use in this study can partly be attributed to its multiple dosing in patients thereby increasing the risk of toxicity as subsequent doses are taken by subjects even when blood steady state are attained.[53]

The positive association between NSAIDs doses and nephrotoxicity in the study agrees with previous findings [5, 30, 52] High doses lead to higher plasma drug concentration, greater PG inhibition with its consequences. The more severe nephrotoxicity seen in participants who combined NSAIDs could be related to the multiple pathophysiologic mechanisms involving multiple enzymatic activities leading to the production of endonucleases and disruption of the cytoskeletal frame of the cellular structure, which in the kidneys could compromise the excretory, endocrine and synthetic functions. [5, 52]

Some limitations we encountered included the fact that advance imaging techniques like magnetic resonance imaging or a computed tomography for the determination of SICK were not done on account of cost, as it applies to urine osmolality. With the cross sectional design of the study, kidney function test were not conducted to confirm chronicity of kidney dysfunction. Estimated duration and frequency of NSAIDs use, given by participants may not be very reliable. Patients may occasionally decide to skip, reduce or increase dosage when pain eases or worsen.

Information on co-morbid conditions were either self-reported or from participants' case files, undiagnosed diseases that affect results of investigations.

## **Conclusion**

NSAIDs are cheap, very common and often abused OTC drugs and hypertension and kidney disease could complicate their use particularly when used in states of stress, exercises, dehydration, infections, and in prolonged and multiple drug therapy. Prescribers should be more aware of their nephrotoxicity and conditions under which this is enhanced and should therefore consider dosage reduction, single NSAIDs therapy and finding alternatives to “pain killers” Ibuprofen was the most nephrotoxic while Diclofenac was the least nephrotoxic. Periodic kidney function assessment is needed prior to, during prolonged use, and when nephrotoxicity or the risk for it is increased.

## **Recommendations**

1. More media campaigns, advocacy and net-working should be encouraged to increase awareness of kidney diseases and to institute screening programmes for early detection of disease with prompt referral to the nephrologist.
2. Larger studies involving all races should be carried out to ascertain the sensitivity of screening tools like ACR.
3. Where NSAIDs use becomes inevitable, efforts should be made to reduce the duration, dosages and frequency of use, and combination therapy.
4. Periodic (annual) kidney function test should be conducted on patients on prolonged NSAIDs therapy in conjunction with a nephrologist.

**Funding:** None

**Conflict of interest:** The authors declare no conflict of interest in the publication of this paper.

### **Ethical Approval:**

The study was approved by the Human Ethics Committee of the Federal Medical Centre, Abeokuta, Nigeria with the reference code: NREC/08/04/2010-2015 and FMCA/238/HREC/09/2015.

### **Consent**

As per international standard or university standard, patients' written consent has been collected and preserved by the author(s).

**Table 1: Clinical and Laboratory findings in the study participants**

Variables	NSAIDs users (Mean $\pm$ SD) n=100	Controls (M $\pm$ SD) n=100	t-test	P-value
BMI, kg/m <sup>2</sup>	27.22 $\pm$ 14.43	26.15 $\pm$ 5.69	1.11	0.03
Systolic BP, mmHg	127.16 $\pm$ 8.67	122.55 $\pm$ 10.6	2.01	0.04
Diastolic BP, mmHg	79.16 $\pm$ 5.32	74.82 $\pm$ 4.44	2.26	0.03
Sodium, mmol/L	134.56 $\pm$ 7.62	136.87 $\pm$ 1.43	0.06	0.08
Potassium, mmol/L	4.10 $\pm$ 2.82	3.82 $\pm$ 6.04	2.01	0.03

Chloride, mmol/L	102.67 ± 8.24	96.15 ± 1.88	4.23	<0.001
Bicarbonate, mmol/L	22.56 ± 10.47	23.94 ± 9.01	2.22	0.04
Urea, mmol/L	6.30 ± 2.23	5.34 ± 2.11	2.74	0.04
Creatinine, umol/L	98.12 ± 10.16	77.81 ± 9.88	7.83	<0.001
eGFR, mL/min	87.83 ± 30.72	115.01 ± 26.92	9.84	<0.001
Haemoglobin concentration, g/dL	12.78 ± 1.26	13.83 ± 1.42	2.77	0.02
Serum bicarbonate, mmol/L	21.56 ± 5.52	23.03 ± 6.17	3.24	0.001
24 hour urine protein, (mg/day)	562.52 ± 28.16	212.52 ± 18.16	8.86	<0.001
CrCl, (mL/min)	76.31 ± 11.08	118.18 ± 11.26	9.52	<0.001

*NSAIDs-non-steroidal anti-inflammatory drugs, BMI-body mass index, BP-blood pressure, GFR-estimated glomerular filtration rate, CrCl-creatinine clearance*

**Table 2: Relationship between the duration of NSAIDs use and markers of kidney function**

Variables	1-6 months	7-12 months	1-5 years	≥5 years	P-value
	Frequency (%)	Frequency (%)	Frequency (%)	Frequency (%)	
	23 (23)	36 (36)	35 (35)	6 (6)	
Systolic BP, mmHg	121.85 ± 13.16	123.76 ± 13.22	132.52 ± 11.87	136.67 ± 18.39	0.001
Diastolic BP, mmHg	74.98 ± 8.56	77.44 ± 9.47	82.53 ± 10.12	86.05 ± 12.38	0.001
Estimated eGFR	96.29 ± 26.30	92.45 ± 30.53	80.98 ± 30.75	67.51 ± 38.24	<0.001
Hemoglobin, g/dL	13.36 ± 4.27	13.05 ± 4.03	12.23 ± 3.51	11.05 ± 3.56	0.002

*NSAIDs-non-steroidal anti-inflammatory drugs, BP-blood pressure, eGFR-estimated glomerular filtration rate*

Table 3: Relationship between the doses and number of NSAIDs and kidney function (ACR

>3.4mg/mmol

Variables	Frequency n=100 (%)	ACR <3.4 mg/mmol n=82 (%)	ACR >3.4 mg/mmol n=18 (%)	X <sup>2</sup>	P-value
<b>Aceclofenac, mg/day</b>					
100	1 (1.00)	1 (1.22)	0 (0.0)	0.08	0.07*
200	2 (2.00)	2 (2.44)	0 (0.0)		
<b>Diclofenac, mg/day</b>					
50	10 (10.00)	10 (12.20)	0 (0.00)	0.06	0.08
100	14 (14.00)	13 (15.85)	1 (5.56)		
<b>Ibuprofen, mg/day</b>					
600	4 (4.00)	4 (4.80)	0 (0.00)	7.32	<0.001
1200	2 (2.00)	0 (0.00)	2 (11.11)		
<b>Ketovail, mg/day</b>					
100	4 (4.00)	4 (4.80)	0 (0.00)	3.47	0.04
200	6 (6.00)	4 (4.80)	2 (11.11)		
<b>Miloxicam, mg/day</b>					
7.5	5 (5.00)	5 (6.10)	0 (0.00)	0.09	0.06
15	11 (11.0)	10 (12.20)	1 (5.56)		
<b>Combined NSAIDs</b>					
	41 (41.0)	29 (35.36)	12 (66.66)	7.15	<0.001

ACR=albumin creatinine ratio, \*-fisher's exact test

Table 4: Correlates of kidney dysfunction in NSAIDs users

Variables	NSAIDs users without KD n=78 (%)	NSAIDs users with KD n=22 (%)	OR	95% CI	P-value
<b>Sex</b>					
Males	40 (81.63)	9 (18.37)	2.85	1.78-4.14	0.03
Females	38 (74.51)	13 (25.49)			
<b>Age, years</b>					
<60	76 (84.44)	14 (15.56)	8.65	3.61-12.73	<0.001
≥60	2 (20.0)	8 (80.0)			
<b>Number of NSAIDs</b>					
1	51 (86.44)	8 (13.56)	5.83	5.79-10.96	<0.001
≥2	27 (65.85)	14 (34.15)			
<b>Duration of NSAIDs use, years</b>					
≤1	56 (94.91)	3 (5.09)	6.37	1.38-7.57	<0.001
>1	22 (53.66)	19 (41.34)			
<b>Herbal remedies</b>					
Yes	0 (0.0)	11 (100.0)	9.62	4.82-13.68	<0.001
No	78 (87.64)	11 (12.36)			
<b>Arthritis</b>					
Yes	26 (68.42)	12 (31.58)	4.22	2.49-6.11	<0.001

No	52 (83.87)	10 (16.13)			
Haemoglobin concentration, g/dL					
<13	16 (47.06)	18 (52.94)	7.69	3.66-13.54	<0.001
≥13	62 (93.94)	4 (6.06)			
Serum Bicarbonate, mmol/L					
<22	8 (38.10)	13 (61.90)	8.2	2.99-13.69	<0.001
>22	70 (88.61)	9 (11.39)			

*KD*-kidney dysfunction, *OR*-odds ratio, *CI*-confidence interval, *NSAIDs*-non-steroidal anti-inflammation drugs, *ACR*-albumin creatinine ratio

**Table 5: Multivariate Logistic Regression Analysis**

Variables	OR	95% CI	P-value
Age (years)	2.24	1.05-2.45	0.01
Gender	0.62	0.08-0.94	0.09
Duration on NSIADs	2.46	1.32-2.76	0.01
Combination drugs	9.46	1.14-11.28	<0.001
Ibuprofen	1.78	1.81-2.65	0.02
Herbal remedies	0.04	0.03-0.058	0.12

*OR*=odds ratio, *CI*=confidence interval, *NSAIDs*=non-steroidal anti-inflammatory drugs

## References

1. Baker M, Perazella MA. NSAIDs in CKD: Are They Safe? *Am J Kidney Dis* 2020; 76(4): 546-557 DOI: 10.1053/j.ajkd.2020.03.023

2. Agaba EL, Agaba PA, Wigwe CM. Use and abuse of Analgesic in Nigeria. Niger J Med 2004; 13(4): 379-382.
3. Modig S, Elmstahl. Kidney function and use of non-steroidal anti-inflammatory drugs among elderly people: a cross-sectional study on potential hazards for an at risk population. Int J Clin Pharm 2018; 40(4): 870-877
4. Ritter J, Lewis L, Mant T, Ferro A. Analgesics and the control of pain *In: A Textbook of Clinical Pharmacology and Therapeutics, 5Ed Imprint CRC Press. eBook ISBN9780429167294*
5. Uduagbamen PK, Salako BL, Hamzat MA, Kadiri S, Arogundade FA. Kidney Function in Frequent Users of Non-steroidal anti-inflammatory Drugs (NSAIDs). Open J Int Med 2020; 10(1): 69-82
6. Paulose-Ram R, Hirsch R, Dillon C, Gu Q. Frequent Monthly Use of Selected Non-Prescription and Prescription Non-Narcotic Analgesics Among U.S. Adults. Pharmacolepidemiol Drug Saf 2005; 14(4): 257-66.
7. Sanya EO, Kolo PM, Makusidi MA. A survey on doctors' knowledge and attitude of treating chronic pain in three tertiary hospitals in Nigeria Niger Med J 2014; 55 (2): 106-110
8. Hamzat TK, Ajala AO. Interaction between anti-hypertensives and non-steroidal anti-inflammatory drugs: Implication in management of osteoarthritis and opinion on a compromise therapy; Internet J Medical Update 2010;5(1): 42-47.
9. Patino FG, Olivieri J, Allison JJ. Non-steroidal anti-inflammatory drug toxicity monitoring and safety practices. J Rheumatol. 2003; 30(12): 2680–2688.

10. Zhao Y, Denise M. Boudreau, Andrew N. Freedman. Trends in the use of aspirin and non-steroidal anti-inflammatory drugs in the general U.S. population. *Pharmacoepidemiol and drug Safety* 2013; 23(1): 43-50
11. Chang YK, Liu JS, Hsu YH, Tarng DC, Hsu CC. Increased Risk of End-Stage Renal Disease (ESRD) Requiring Chronic Dialysis is Associated With Use of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): Nationwide Case Crossover Study. *Medicine (Baltimore)*.2015; 94(38), e1362
12. Martínez S, Aguilo A, Moreno C, Lozano L, Tauler P. Use of Non-Steroidal Anti-Inflammatory Drugs among Participants in a Mountain Ultramarathon Event. *Sports (Basel)*.2017; 5 (1): pii: E11
13. Smith JH, Robinson S, Percy M. Renal response to heat, dehydration and exercise. *J Appl Physiol* 1952;4: 659-665
14. Morley JE. Dehydration, Hypernatremia, and Hyponatremia. *Clin Geriatr Med* 2015; 31(3): 389-399 DOI: 10.1016/j.cger.2015.04.007
15. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, 3rd, Feldman HI, et al. CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) A new equation to estimate glomerular filtration rate. *Ann Intern Med*. 2009;150: 604–12
16. KDIGO Clinical Practice Guidelines for the Management of Blood Pressure in Chronic Kidney Disease. *Kidney Int Practice Guidelines* 2021; 99(3): S1-S87
17. Lee YB, Lee JS, Hong SH, Kim JA, Roh E, Yoo HJ, et al. Optimal blood pressure for patients with chronic kidney disease: a nationwide population-based cohort study *Sci Rep*. 2021; 11: 1538. doi: 10.1038/s41598-021-81328-y
18. Pippitt K, Li M, Gurgle HE. Diabetes Mellitus: Screening and Diagnosis. *Am Fam Physician* 2016; 93(2): 103-109

19. Cascio MJ, DeLoughery TA. Anemia: Evaluation and Diagnostic Tests Med Clin North Am 2017; 101(2): 263-284 DOI: [10.1016/j.mcna.2016.09.003](https://doi.org/10.1016/j.mcna.2016.09.003)
20. Uduagbamen PK1, Oyelese AT, Alalade BA, Ogunkoya JO, Adesuyi YO, Timothy OR. Anemia of Chronic Kidney Disease: Pattern, Prevalence and Clinical Correlates. A Single Center Cross sectional Study in South western Nigeria.
21. Hunter LJ, Wood DM, Dargan PI. The patterns of toxicity and management of acute nonsteroidal anti-inflammatory drug (NSAID) overdose. Open Access Emerg Med. 2011; 3: 39–48. doi: [10.2147/OAEM.S22795](https://doi.org/10.2147/OAEM.S22795)
22. Lamb EJ, MacKenzie E, Stevens PE. How should proteinuria be detected and measured? Ann Clin Biochem 2009; 46: 205-217
23. Medina-Rosas J, Gladman DD, Su J, Sabapathy A, Urowitz MB, Touma Z. Utility of untimed single urine protein/creatinine ratio as a substitute for 24-h proteinuria for assessment of proteinuria in systemic lupus erythematosus. Arthritis Research & Therapy. 2015; 17: 296.
24. Uduagbamen PK, Hamzat MA, Ehioghae O. The Urine in Kidney Function Assessment among Nigerians in Health and with Frequent Use of Non-steroidal Anti-inflammatory Drugs. RJHS 2020; 8(4): 225-233
25. Zheng L, Du X. Non-steroidal anti-inflammatory drugs and hypertension Cell Biochem Biophys 2014; 69(2): 209-11. DOI: [10.1007/s12013-013-9791-5](https://doi.org/10.1007/s12013-013-9791-5)
26. Schwarz A, Krause PH, Kunzendrof V, Keller F, Distler A. The outcome of acute interstitial nephritis: risk factors for the transition from acute to chronic interstitial nephritis. Clin Nephrol 2000; 54: 179-90
27. Livio F, Biollaz J, Burnier M. Renal function estimation by MDRD equation: interest and limitations for drug dosing. Rev Med Suisse 2008 Nov 26;4(181):2596-600.

28. Uduagbamen PK, Oyelese AT AdebolaYusuf AO, Salami OF, Nwinee CM, Ogunmola MI, et al. The Pattern of Eosinophil Count among Nigerians with Frequent use of the Commonly Available Non-steroidal Anti-inflammatory Drugs. *Int J Clin Med* 2020; 11(10): 605-617 doi: 10.4236/ijcm.2020.1110051
29. Han Y, Balkrishnan R, Hirth RA, Hutton DW, He K, Steffick DE, et al. Assessment of Prescription Analgesic Use in Older Adults With and Without Chronic Kidney Disease and Outcomes. *JAMA. Netw Open* 2020;3(9):e2016839. doi: 10.1001/jamanetworkopen.2020.16839.
30. De Broe ME, Elseviers MM. Over-the-counter analgesic use. *J Am Soc Nephrol* 2009; 20(10): 2098–2103.
31. Ulasi I. Gender bias in access to healthcare in Nigeria: a study of endstage renal disease. *Trop Doct.* 2008;38(1):50-2.
32. Chu T. Gender Difference in Pharmacokinetics. *US Pharmacokinetics* 2014;39(9): 40-43
- Franconi F, Campesi I. Pharmacogenomics, pharmacokinetics and pharmacodynamics: interaction with biological differences between men and women. *Br J Pharmacol.* 2014; 171: 580-594.
33. Gheun-Ho Kim. Renal Effects of Prostaglandins and Cyclooxygenase-2 Inhibitors. *Electrolyte Blood Press.* 2008; 6(1): 35-41
34. Kovesdy CP, Furth SI, Zoccali C,<sup>4</sup> and on behalf of the World Kidney Day Steering Committee\* Obesity and Kidney Disease Hidden Consequences of the Epidemic. *Can J Kidney Health Dis.* 2017; 4: 2054358117698669. doi: 10.1177/2054358117698669
35. Hoy WE, Bertram JF, Hughson MD. Nephron Hypertrophy and Glomerulosclerosis in Normal Donor Kidneys. *Clin J Am Soc Nephrol.* 2014; 9(11): 1832–1834. doi: 10.2215/CJN.08680814

36. Volker Vallon Scott C. Thomson. Renal Function in Diabetic Disease Models: The Tubular System in the Pathophysiology of the Diabetic Kidney. *Annu Rev Physiol.* 2012; 74: 10.1146/annurev-physiol-020911-153333. doi: 10.1146/annurev-physiol-020911-153333
37. Pirkle JL, Freedman BL. Hypertension and chronic kidney disease: controversies in pathogenesis and treatment. *Minerva Urol Nefrol* 2013; 6(1): 37-50
38. Musemwa N, Gadegbeku CA. Hypertension in African Americans. *Curr Cardiol Rep* 2017; 19(12): 129 DOI: [10.1007/s11886-017-0933-z](https://doi.org/10.1007/s11886-017-0933-z)
39. Maraboto C, Keith C Ferdinand. Update on hypertension in African-Americans. *Prog Cardiovasc Dis* 2020; 63(1): 33-39. doi: 10.1016/j.pcad.2019.12.002.
40. Firestein GSM, Budd RC, Gabriel RC, McInnes IB, O'Dell JR. Prostanoid biology and its therapeutic targeting In: Crofford LJ Kelly's Textbook of Rheumatology; Philadelphia: Saunders 2013; pg 871-893.9
41. Jayasinghe K, White SM, Kerr PG, MacGregor D, Stark Z, Wilkins E *et al.* Isolated proteinuria due to *CUBN* homozygous mutation – challenging the investigative paradigm. *BMC Nephrology* 2019; 20: 330
42. Jiang L, Xu L, Song Y, Jianzhong L. Mao J, Zhao AZ *et al.* Calmodulin-dependent Protein Kinase II/Camp Response Element-binding Protein/Wint/ $\beta$ -Catenin Signalling Cascade Regulates Angiotensin II-induced Podocytes Injury and Albuminuria. *J Biol Chem* 2013; 288(32): 23368-23379
43. Amira CO, Sokunbi DOB, Dolapo D, Sokunbi A. Prevalence of obesity, overweight and proteinuria in an urban community in South West Nigeria. *Nig Med J* 2011; 52(2): 110-113143
44. Mérida E, Praga M. NSAIDs and Nephrotic Syndrome. *Clin J Am Soc Nephrol.* 2019; 14(9): 1280–1282. doi: 10.2215/CJN.08090719

45. Vega J, Goecke H, Mendez GP, Guarda FI. Nephrotic syndrome and Acute Tubular Necrosis Due to Meloxicam Use. *Renal failure* 2012; 34(10): 1344-1347
46. Ghosh R, Alajbegovic A, Gomes AV. NSAIDs and Cardiovascular Disease: Role of Reactive Oxygen Species. *Oxid Med Cell Longev* 2015; 2015: 536962
47. Mikolasevic I, Žutelija M, Mavrinac V, Orlic L. Dyslipidemia in patients with chronic kidney disease: etiology and management *Int J Nephrol Renovasc Dis* 2017 Feb 7;10:35-45.  
doi: 10.2147/IJNRD.S101808.
48. Goldstein JL, Chan FKL, Scheiman JM. Haemoglobin decrease in NSAIDS users over time: an analysis of two large outcome trials. *Aliment Pharmacol Ther* 2011; 34(7): 808-816
49. Laras H, Haddoum F, Baghdali FY, Gagi N, Koceir EHA, Bitam A. Prevalence of malnutrition and absolute and functional iron deficiency anemia in nondialysis-dependent chronic kidney disease and hemodialysis Algerian patients. *Nephrol Ther* 2022; S1769-7255(22)00082-7. doi: 10.1016/j.nephro.2022.03.001.
50. Uduagbamen PK, AdebolaYusuf AO, Ahmed SI, Thompson MU, Alalade BA, Ogunmola MI, Falana TE, Omokore OA, Emmanuel CC. Gender Differences in Chronic Kidney Disease. Findings from a Two Center Study in Nigeria. *Arch Pharm Pract* 2022; 13(2): 69-77.  
<https://doi.org/10.51847/EOLTIIdNXtq>
51. Uduagbamen PK. Non-Steroidal Anti-Inflammatory Drugs and the Kidneys in Health and the Risk of Progression to Kidney Disease: A Mini Review *Clin Nephrol Res* 2021; 5(5): 1-3
52. Horl WH. Non-steroidal Anti-inflammatory Drugs and the Kidneys. *Pharmaceuticals (Basel)* 2010; 3(7): 2291-23
53. Liu AC, Chang Y, Zuckerman JE, Kalantar-Zadeh K, Ghobry LM, Hanna RM. Ibuprofen-associated minimal change disease and acute interstitial nephritis with possibly linked membranous

glomerulonephritis. SAGE Open Med Case Rep. 2021; 9:

2050313X211025145. doi: 10.1177/2050313X211025145